Corrigendum to "Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment" [Heliyon Volume 10, Issue 19, October 2024, Article e37867].

Shiraiwa N; Kano S

doi:10.1016/j.heliyon.2025.e44157

← 뒤로

Corrigendum to "Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment" [Heliyon Volume 10, Issue 19, October 2024, Article e37867].

Heliyon 2025 Vol.11(17) p. e44157

Shiraiwa N, Kano S

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

[This corrects the article DOI: 10.1016/j.heliyon.2024.e37867.].

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Shiraiwa N, Kano S (2025). Corrigendum to "Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment" [Heliyon Volume 10, Issue 19, October 2024, Article e37867].. Heliyon, 11(17), e44157. https://doi.org/10.1016/j.heliyon.2025.e44157

MLA Shiraiwa N, et al.. "Corrigendum to "Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: A unique setting in the initial adoption phase in Japan allowing testing only after standard treatment" [Heliyon Volume 10, Issue 19, October 2024, Article e37867].." Heliyon, vol. 11, no. 17, 2025, pp. e44157.

PMID 41497839

DOI 10.1016/j.heliyon.2025.e44157

Abstract

[This corrects the article DOI: 10.1016/j.heliyon.2024.e37867.].